BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

Core Viewpoint - BrainStorm Cell Therapeutics Inc. has appointed Dr. Hartoun Hartounian as the new EVP and COO, which is expected to enhance the company's operational efficiency and support the commercial readiness of its ALS treatment, NurOwn® [1][2] Company Overview - BrainStorm Cell Therapeutics is a developer of autologous adult stem cell therapeutics aimed at treating neurodegenerative diseases, particularly ALS [4] - The company holds exclusive rights to the NurOwn® technology platform, which has received Orphan Drug designation from the FDA and EMA for ALS treatment [4] Leadership Appointment - Dr. Hartounian has over 32 years of experience in the biopharmaceutical industry, particularly in cell and gene therapy [1][2] - His previous achievements include founding BioCentriq, which was acquired for $73 million in 2022, and leading multiple biotechnology companies [1][2] Responsibilities and Expectations - In his new role, Dr. Hartounian will oversee all operational aspects, including CMC and commercialization, to streamline logistics and navigate complexities [2] - The company anticipates that Dr. Hartounian's expertise will be crucial in advancing NurOwn and achieving strategic objectives [2] Clinical Development - BrainStorm has completed a Phase 3 trial for NurOwn in ALS, which investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells [4][5] - The company has also conducted a Phase 2 trial for progressive MS, supported by grants from relevant organizations [5]